Two new research projects are moving forward at the U-M Life Sciences Institute, with support from philanthropic funds established specifically to high-risk, high-reward research.
A quarterly column on the LSI’s work to cultivate a diverse, equitable and inclusive climate
Researchers have demonstrated that a natural compound produced by lichens can block the activity of a protein that is central to the gene-activation process. The research, conducted in human-derived breast cancer cells, points to this protein as potential therapeutic target.
Scientists have identified a protein called the melanocortin 3 receptor as a potential drug target for treating obesity and eating disorders such as anorexia nervosa.
A new study from the University of Michigan offers insights into how neural circuitry in the brain operates and responds to feeding and hunger in real-time.
The building that houses the LSI will be named Mary Sue Coleman Hall. This naming recognizes her enduring commitment to the sciences and her role in spearheading the Life Sciences Institute, as well as her highly successful tenure as president of U-M.
As we marked our first “Panniversary,” LSI professor and research associate dean Bing Ye reflected on how the institute has navigated a year of reduced research efforts, and the potential long-term impacts — both good and bad — on the scientific enterprise.
Researchers in the lab of Wenjing Wang, Ph.D., have designed a new chemical tool that can detect the presence of opioids at a cellular level.
A team of researchers has discovered an antibody that blocks the dengue virus’s ability to cause disease in mice. The findings open the potential for developing effective treatments and designing a vaccine for dengue and similar diseases.